Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04681066 · ClinicalTrials.gov registry record · Phase 2

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

A Phase 2 study of Acute Pancreatitis and Systemic Inflammatory Response Syndrome, sponsored by CalciMedica.

Completed
Registry status
Phase 2
Development phase
216
Enrollment target
20
Study locations

NCT04681066 is a Phase 2 study of Acute Pancreatitis and Systemic Inflammatory Response Syndrome that has completed, run by CalciMedica. The registered enrollment target is 216 participants, below the 2,297-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04681066, a Phase 2 study of Acute Pancreatitis and Systemic Inflammatory Response Syndrome, has completed, sponsored by CalciMedica.

COMPLETED
Registry status
Phase 2
Development phase
216 participants
Enrollment target
20
Study locations

Study Summary

Approximately 216 patients with acute pancreatitis and accompanying SIRS will be randomized at approximately 30 sites. Patients will be randomly assigned to either Auxora at one of three dose levels or one of three placebo volumes to maintain the double-blind. Study drug infusions will occur every 24 hours for three consecutive days for a total of three infusions. Patients will remain hospitalized as per standard of care and once discharged will be asked to complete a daily meal diary and return for a Day 30 safety assessment. It is recommended that patients randomized in the study should not be discharged from the hospital until solid food is tolerated, abdominal pain has resolved or been adequately controlled, and there is no clinical evidence of infection necessitating continued hospitalization.

Interventions

  • OTHER Placebo
  • DRUG CM-4620 Injectable Emulsion or CM-4620-IE

Study Locations (20)

California

  • Long Beach Medical Center - Long Beach
  • LA County Hospital - USC - Los Angeles
  • Cedars Sinai - Los Angeles
  • University of California at Irvine Medical Center - Orange
  • Harbor UCLA Medical Center - Torrance
  • Torrance Memorial Medical Center - Torrance

Florida

  • Sarasota Memorial Health Care System - Sarasota
  • Tampa General Hospital - Tampa

Minnesota

  • Methodist Hospital - Saint Louis Park
  • Regions Hospital - Saint Paul

Missouri

  • University of Missouri School of Medicine - Columbia
  • Washington University School of Medicine - St Louis

New York

  • Northshore University Hospital - Manhasset
  • Icahn School of Medicine at Mount Sinai - New York

Connecticut

  • The Stamford Hospital - Stamford

Idaho

  • St. Luke's Regional Medical Center - Boise

Illinois

  • Northwestern University Hospital - Chicago

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2021-03-24
Est. Completion 2024-05-15
Phase Phase 2

Sponsor

CalciMedica

6 total trials

What the Registry Record Tells You About NCT04681066

The ClinicalTrials.gov registry entry for NCT04681066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,297-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (91% lower). The listed sponsor is CalciMedica, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Pancreatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04681066 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04681066 about?

NCT04681066 is a clinical study titled "A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS". Approximately 216 patients with acute pancreatitis and accompanying SIRS will be randomized at approximately 30 sites. Patients will be randomly assigned to either Auxora at one of three dose levels or one of three placebo volumes to maintain the double-blind. Study drug infusions will occur every 2...

What is the current status of trial NCT04681066?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2021-03-24. Estimated completion is 2024-05-15.

What conditions does trial NCT04681066 study?

This clinical trial studies the following conditions: Acute Pancreatitis, Systemic Inflammatory Response Syndrome.

What interventions are being tested in trial NCT04681066?

The interventions under investigation include: Placebo (OTHER), CM-4620 Injectable Emulsion or CM-4620-IE (DRUG).

Who is sponsoring clinical trial NCT04681066?

This trial is sponsored by CalciMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04681066 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.